|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||






* Lipid Research Group, Heart Research Institute, Camperdown, Sydney, New South Wales 2050, Australia
Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104
Department of Immunology, Scripps Research Institute, La Jolla, CA 92037
** Department of Medicine, University of Sydney, Sydney, New South Wales 2006, Australia

Department of Medicine, University of Melbourne, Melbourne, Victoria 3010, Australia
Published, JLR Papers in Press, February 1, 2005. DOI 10.1194/jlr.M400212-JLR200
1 To whom correspondence should be addressed. e-mail: a.jahangiri{at}hri.org.au
| ABSTRACT |
|---|
|
|
|---|
These results establish that the phospholipase activity of EL remodels plasma HDLs and rHDLs into smaller particles without mediating the dissociation of apolipoproteins.
Abbreviations: apoA-I, apolipoprotein A-I; CE, cholesteryl ester; CETP, cholesteryl ester transfer protein; EL, endothelial lipase; RAM-Fc, rabbit anti-mouse Fc; rHDL, reconstituted high density lipoprotein; TG, triacylglycerol; UC, unesterified cholesterol
Supplementary key words phospholipids hydrolysis lipoprotein metabolism
| INTRODUCTION |
|---|
|
|
|---|
EL differs from the other triglyceride lipase gene family members in that it has high phospholipase and low TG lipase activity (1, 7). The principal substrates of EL are HDLs (7). EL also regulates HDL levels. For example, overexpression of EL in mice transgenic for human apolipoprotein A-I (apoA-I) reduces HDL-cholesterol and apoA-I levels, whereas infusion of anti-EL polyclonal antibodies into mice transgenic for human apoA-I increases plasma levels of total cholesterol, HDL-cholesterol, phospholipids, and apoA-I (1, 8). HDL-cholesterol levels are also increased in EL knockout mice. This is accompanied by a compensatory upregulation of HL and LPL activities (9).
Previous work from this laboratory has shown that HL remodels TG-enriched HDLs into small particles in a process that is accompanied by the dissociation of apoA-I (1012). This is largely attributable to the TG lipase activity of HL depleting the HDLs of core lipids and generating an excess of surface constituents. This imbalance is corrected by the dissociation of lipid-poor apoA-I from the particles (1012). Given that EL has very low TG lipase activity, the aim of the present study was to determine whether its high phospholipase activity is sufficient to remodel HDLs into small particles and mediate the dissociation of lipid-free or lipid-poor apoA-I.
As EL does not hydrolyze all HDL phospholipids equally well (13), it was important to use particles in which the phospholipid content was well defined. To ensure that interpretation of the results was unequivocal, it was also necessary to use HDLs that did not contain TG. This was achieved by using homogeneous preparations of spherical reconstituted HDLs (rHDLs) that were comparable in size and composition and contained only cholesteryl esters (CEs) in their core (14, 15). When these rHDLs were incubated with EL, phospholipids were the only constituents hydrolyzed.
The HDLs in human plasma have been classified on the basis of apolipoprotein composition into two main populations of particles: those containing apoA-I but not apoA-II [(A-I)HDLs] and those containing apoA-I as well as apoA-II [(A-I/A-II)HDLs] (16). A minor population of HDLs that contain apoA-II but not apoA-I [(A-II)HDLs] has also been identified (17). Recent studies carried out in this laboratory have shown that the rate of EL-mediated phospholipid hydrolysis in (A-I/A-II)rHDLs is enhanced relative to that in (A-I)rHDLs and that EL-mediated hydrolysis of (A-II)rHDL phospholipids is minimal (18). These results raised the possibility that apolipoproteins may regulate the EL-mediated remodeling of HDLs. To determine whether this was the case, the remodeling of (A-I)rHDLs, (A-I/A-II)rHDLs, and (A-II)rHDLs was investigated.
The results confirmed that EL hydrolyzed (A-I/A-II) rHDL phospholipids to a greater extent than the phospholipids in (A-I)rHDLs and that there was minimal hydrolysis of the phospholipids in (A-II)rHDLs. EL also remodeled the (A-I/A-II)rHDLs and (A-I)rHDLs, but not the (A-II)rHDLs, into smaller particles. This remodeling was not accompanied by the dissociation of either apoA-I or apoA-II from the particles. Comparable results were obtained when HDLs from human plasma were incubated with EL.
| EXPERIMENTAL PROCEDURES |
|---|
|
|
|---|
Isolation of LCAT
LCAT was prepared from samples of pooled, expired, autologously donated human plasma (21). LCAT activity was assessed using discoidal rHDLs containing POPC (Sigma), unesterified cholesterol (UC; Sigma), apoA-I, and a trace amount of radiolabeled UC ([1
,2
-3H]UC; Sigma) as the substrate (22). The preparation of LCAT used in this study generated 286 nmol CE/ml LCAT/h.
Preparation of spherical (A-I)rHDLs, (A-I/A-II)rHDLs, and (A-II)rHDLs
Discoidal rHDLs containing POPC, UC, and either apoA-I or apoA-II (initial POPC/UC/protein molar ratio of 100:5:1) were prepared by the cholate dialysis method (23). Spherical (A-I)rHDLs containing CEs as the only core lipid were prepared by incubating the discoidal rHDLs with LDL and LCAT as described previously (14). Spherical (A-II)rHDLs were prepared by displacing all of the apoA-I from the spherical (A-I)rHDLs with lipid-free apoA-II (14). As judged by nondenaturing gradient gel electrophoresis, the spherical (A-I)rHDL and (A-II)rHDL preparations did not contain lipid-free apolipoproteins.
Spherical (A-I/A-II)rHDLs, with both apoA-I and apoA-II on the same particle, were prepared as described (15). Briefly, discoidal (A-I)rHDLs (45 mg of apoA-I) were incubated at 37°C for 24 h with discoidal (A-II)rHDLs (15 mg of apoA-II), LDL (180 mg of apoB), fatty acid-free BSA (final concentration, 40 mg/ml), ß-mercaptoethanol (final concentration, 4 mM), and LCAT (90 ml) in a final volume of 164 ml. These conditions generated spherical (A-I/A-II)rHDLs and a small amount of spherical (A-I) rHDLs. The rHDLs were isolated by ultracentrifugation in the 1.07 < d < 1.21 g/ml density range, dialyzed against TBS (3 x 1 liter), and subjected to immunoaffinity chromatography on a column containing an anti-human apoA-II polyclonal antibody coupled to CNBr-activated Sepharose 4B (Amersham Biosciences). The (A-I)rHDLs, which did not bind to the column, were eluted with TBS. The (A-I/A-II)rHDLs that bound to the column were eluted with 0.1 M acetic acid (pH 2.7) and adjusted immediately to pH 7.4 with 1 M Tris, pH 11.0 (final concentration, 0.1 M). The (A-I/A-II)rHDLs were concentrated 30-fold by ultrafiltration at 4°C (Millipore, Bedford, MA).
Isolation of human (A-I)HDLs, (A-I/A-II)HDLs, and HDL2 from human plasma
HDLs were isolated from human plasma by sequential ultracentrifugation in the 1.07 < d < 1.21 g/ml density range. (A-I/A-II)HDLs were separated from (A-I)HDLs by anti-apoA-II immunoaffinity chromatography as described above for rHDLs. When the (A-I)HDLs and (A-I/A-II)HDLs were subjected to nondenaturing gradient gel electrophoresis, the (A-I)HDLs, but not the (A-I/A-II)HDLs, were found to contain lipid-free apoA-I. As lipid-free apoA-I was not present in the ultracentrifugally isolated HDLs, we concluded that it had dissociated from the (A-I)HDLs during immunoaffinity chromatography. As one of the aims of this study was to determine whether EL mediated the dissociation of lipid-free apoA-I from (A-I)rHDLs, these particles were not used further. For this reason, ultracentrifugally isolated HDL2 (1.07 < d < 1.12 g/ml), which contains mainly (A-I)HDLs and only a small amount of (A-I/A-II)HDLs, was used instead of (A-I)HDLs in the plasma HDL incubations. As judged by nondenaturing gradient gel electrophoresis, HDL2 did not contain lipid-free apoA-I. The HDL2 were dialyzed against 3 x 1 liter of TBS, pH 7.4, before use.
Expression of EL
COS cells were grown in DMEM with 10% fetal bovine serum and 1% antibiotic/antimycotic at 37°C and 5% CO2. Before infection, cells were brought to 90% confluence on 150 mm plates. Growth medium was removed and the cells were washed with 10 ml of serum-free DMEM without phenol red, then incubated with recombinant adenovirus encoding EL in 5 ml of the same medium at a multiplicity of 3,000 particles/cell. Two hours later, 9 ml of serum-free medium without phenol red, containing 10 U/ml heparin, was added to each of the plates. At 47.5 h after infection, an additional 10 U/ml heparin (280 µl of 500 U/ml) was added, and the cells were incubated for another 30 min. Medium was collected and clarified by centrifugation at 2,000 rpm for 10 min in 50 ml conical tubes, then frozen in 1 ml aliquots at 80°C. EL activity was assessed using as a substrate spherical (A-I) rHDLs containing only CE in the core and POPC as the only phospholipid. The rHDLs (final concentration, 1 mM phospholipid) were incubated with 20 µl of EL for 1.5 h at 37°C. NEFA mass was assayed using a commercially available kit (Wako Pure Chemical Industries, Osaka, Japan). The EL used in this study generated 135 nmol NEFA/ml EL/h.
Incubations
All incubations were carried out in 1.5 ml Eppendorf tubes in a shaking water bath maintained at 37°C. Nonincubated control samples were stored at 4°C. When the incubations were complete, the rHDLs were isolated by ultracentrifugation in the 1.07 < d < 1.21 g/ml density range with a single 18 h spin at both the lower and upper densities. The spins were carried out at 100,000 rpm in a TLA-100.2 rotor using a Beckman TL-100 tabletop ultracentrifuge maintained at 4°C. The rHDLs were dialyzed against TBS, pH 7.4, before use.
Gradient gel electrophoresis
Plasma HDL and rHDL diameters were determined by electrophoresis on nondenaturing 3% and 40% polyacrylamide gradient gels prepared according to the method of Rainwater et al. (24). Stokes' diameters were calculated by reference to high molecular weight standards of known size (Amersham Biosciences).
Immunoblotting
HDLs and rHDLs (1 µg of apolipoprotein) were electrophoresed on 3% and 40% nondenaturing gradient gels, transferred electrophoretically to nitrocellulose membranes, and immunoblotted with either sheep anti-human apoA-I or goat anti-human apoA-II polyclonal antibodies (Calbiochem, San Diego, CA). Bound antibodies were detected by enhanced chemiluminescence (Amersham Biosciences).
Surface plasmon resonance analysis
A Biacore 2000 biosensor was used to measure the association rate constant (Ka) of seven unique apoA-I monoclonal antibodies to (A-I)rHDLs and (A-I/A-II)rHDLs. Saturating amounts of rabbit anti-mouse Fc (RAM-Fc) were immobilized on all four flow cells of a CM5 chip using amide coupling (25). The monoclonal antibodies, or an isotype control, were injected and captured by the RAM-Fc at dilutions predetermined to give 400 response units. This injection was followed by injection of the rHDLs. Data were collected at a high collection rate and evaluated by synchronizing the injection time and zeroing the sensogram baselines. Control antibody sensograms were subtracted from each specific antibody sensogram. Each antibody and rHDL pair was evaluated with a 1:1 (Langmuir) model. Microsoft Excel 2000 was used for statistical analysis. The t-test for two-tailed distribution and two-sample unequal variance was used to identify significant differences.
Chemical analyses
All assays were performed on a Roche Diagnostics/Hitachi 902 automatic analyzer (Roche Diagnostics GmbH, Mannheim, Germany). An enzymatic kit was used to measure total cholesterol concentrations (Roche Diagnostics GmbH). ApoA-I, apoA-II, phospholipid, and UC concentrations were determined as described previously (2628).
| RESULTS |
|---|
|
|
|---|
|
|
When plasma HDL2 and (A-I/A-II)HDLs were incubated with EL for 6 h, the HDL2 phospholipid concentration decreased from 291.3 to 178.8 µM, whereas the concentration of the (A-I/A-II)HDL phospholipids decreased from 353.8 to 108.8 µM (results not shown).
Remodeling of rHDLs and plasma HDLs by EL
Nondenaturing gradient gel electrophoresis was used to determine whether the phospholipid hydrolysis mediated by EL is sufficient to remodel the (A-I)rHDLs, (A-I/A-II) rHDLs, and (A-II)rHDLs into smaller particles (Fig. 2)
.
|
The composition of the rHDLs at each time point is presented in Table 2. Incubation in the absence of EL did not affect (A-I)rHDL, (A-I/A-II)rHDL, or (A-II)rHDL composition. When the (A-I)rHDLs and (A-I/A-II)rHDLs were incubated in the presence of EL, their phospholipid content decreased in a time-dependent manner, and there was a concomitant increase in the mass percentage of apolipoproteins. (A-II)rHDL composition was unaffected by incubation with EL.
|
|
|
| DISCUSSION |
|---|
|
|
|---|
The results showed that EL remodels (A-I)rHDLs and (A-I/A-II)rHDLs into smaller particles in a process that is not accompanied by the dissociation of either apoA-I or apoA-II. These observations are consistent with earlier work from this laboratory showing that phospholipase A2 remodels (A-I)rHDLs into small particles without mediating the dissociation of apoA-I (31). In that study, apoA-I dissociated from the rHDLs only when the phospholipid-depleted rHDLs were incubated with Intralipid® and CETP under conditions that depleted the particles of core lipids and generated an excess of constituents on the rHDL surface. When the current results are considered in light of the earlier study, it follows that the lack of dissociation of apoA-I from either the (A-I)rHDLs or the (A-I/A-II)rHDLs is probably attributable to the inability of EL to deplete the rHDLs of core lipids. The very low triglyceride lipase activity of EL makes it likely that this is also the case in vivo. This possibility is strengthened by the results shown in Fig. 4, which show that EL does not mediate the dissociation of either apoA-I or apoA-II from plasma (A-I/A-II) HDLs that contain substantial amounts of TG in their core (Table 1).
The immunoblots shown in Fig. 4B, C indicate that EL did not remodel all of the (A-I/A-II)rHDLs into small particles. This is at odds with the data shown in Fig. 2, which show a quantitative conversion of rHDLs into smaller particles. Together, these results suggest that only a small amount of unmodified (A-I/A-II)rHDLs, which was not sufficient for detection with Coomassie Blue, remained after incubation with EL. These unmodified particles were enriched with apoA-II and apparently resistant to remodeling by EL. This is consistent with an earlier report from this laboratory showing attenuated remodeling of (A-I/A-II)rHDLs by CETP (34). It also suggests that EL-mediated remodeling of (A-I/A-II)rHDLs may generate small particles that are depleted of apoA-II.
Several approaches were used to determine why the size of (A-I)rHDLs and (A-I/A-II)rHDLs decreased in the absence of core lipid depletion. The first possibility was that the reduction in particle size reflected a change in the conformation of apoA-I. ApoA-I is a flexible molecule with a hinged domain that may or may not associate with lipid (35, 36). If the size of an HDL particle decreases, the hinged region of apoA-I may be removed from contact with lipids. This would reduce the surface area requirements of apoA-I, thus enabling it to remain associated with the smaller particles. To determine whether this was the case, surface plasmon resonance was used to compare the conformation of apoA-I in (A-I)rHDLs and (A-I/A-II)rHDLs before and after incubation with EL. These results showed that incubation with EL did not change the conformation of apoA-I in either the (A-I)rHDLs or the (A-I/A-II)rHDLs. Given the high affinity of apoA-II for lipid (37), the possibility that the reduction in (A-I/A-II)rHDL size was caused by a change in the conformation of this apolipoprotein was considered unlikely.
The possibility that the remodeling of rHDLs into small particles was attributable entirely to phospholipid depletion was also investigated. This was achieved by comparing the reduction in rHDL surface area with the decrease in the area occupied by the phospholipids on the particle surface. Incubation with EL reduced the (A-I)rHDL surface area by 22 nm2 (from 249 to 227 nm2) (Fig. 2). To ascertain whether there was a comparable reduction in phospholipid area, it was necessary to determine how many phospholipid molecules were hydrolyzed by EL. The (A-I)rHDLs initially contained three molecules of apoA-I per particle (31). Given that apoA-I did not dissociate from these particles during incubation with EL, it follows that the small conversion products also contained three molecules of apoA-I per particle. As incubation with EL reduced the (A-I)rHDL phospholipid/apoA-I molar ratio from 17:1 to 12:1, it follows that the number of phospholipid molecules in the (A-I)rHDLs decreased from 51 to 36. Assuming that the reduction in rHDL size was associated with a reorganization of the unhydrolyzed phospholipids remaining on the rHDL surface from an expanded (0.75 nm2/molecule) to a condensed (0.45 nm2/molecule) state (38), it follows that the area occupied by phospholipids decreased from 38 to 16 nm2. This 22 nm2 difference corresponds precisely to the decrease in particle surface area. It is also consistent with the reduction in (A-I)rHDL size being attributable to phospholipid depletion and a structural reorganization of the unhydrolyzed phospholipids that remained associated with the particles.
This was also the case for the (A-I/A-II)rHDLs, in which incubation with EL reduced the particle surface area from 278 to 227 nm2 (Fig. 2). Earlier work from this laboratory established that (A-I/A-II)rHDLs contain two molecules of apoA-I and two molecules of apoA-II per particle (15). As two molecules of apoA-II occupy approximately the same area as one apoA-I molecule (39), it is reasonable to assume that the (A-I/A-II)rHDL surface contained the equivalent of three molecules of apoA-I. Incubation with EL decreased the (A-I/A-II)rHDL phospholipid/apoA-I molar ratio from 37:1 to 17:1. This equates to a reduction in the number of phospholipid molecules from
111 to 51. Using the approach outlined above, this translates into a decrease in phospholipid surface area of 60 nm2 (from 83 to 23 nm2). As was the case for the (A-I)rHDLs, this is consistent with the remodeling of (A-I/A-II)rHDLs into smaller particles being attributable to phospholipid depletion.
The present results showed that (A-II)rHDLs are poor substrates for EL. Although this suggests that apoA-II inhibits the phospholipase activity of EL, it is not consistent with the results shown in Fig. 1, which show that EL-mediated phospholipid hydrolysis is increased in (A-I/A-II) rHDLs compared with (A-I)rHDLs. This is consistent with the presence of apoA-II on an rHDL particle that also contains apoA-I enhancing, rather than inhibiting, phospholipid hydrolysis and possibly reflects an increased affinity of EL for the rHDL surface or enhanced access of rHDL phospholipid acyl chains to the active site of the enzyme. This is in contrast with our previous results, which showed that the rate of HL-mediated phospholipid hydrolysis in (A-I/A-II)rHDLs is intermediate between that of (A-II) rHDLs and (A-I)rHDLs (40). These differences most likely reflect variations in EL and HL structure, particularly the lack of homology of their lid regions, which determines substrate specificity (1, 2).
The current results suggest that the role of EL in HDL metabolism is distinct from that of HL. In the case of HL, the phospholipase and triglyceride lipase activities act together to reduce HDL size and promote the dissociation of lipid-free or lipid-poor apoA-I (1012). This apoA-I has the ability to accept unesterified cholesterol and phospholipids from peripheral cells in the first step of reverse cholesterol transport. It also forms new HDLs and thus maintains, or possibly increases, HDL levels. The present results suggest that EL is not able to enhance the initial step of reverse cholesterol transport and is therefore unlikely to contribute to the cardioprotective properties of HDLs.
| ACKNOWLEDGMENTS |
|---|
Manuscript received June 7, 2004 and in revised form December 9, 2004 and in re-revised form January 19, 2005.
| REFERENCES |
|---|
|
|
|---|
-helices in human apolipoprotein A-I: effect on phospholipid association. Biochemistry. 36: 17981806.[CrossRef][Medline]
This article has been cited by other articles:
![]() |
N. Settasatian, P. J. Barter, and K.-A. Rye Remodeling of apolipoprotein E-containing spherical reconstituted high density lipoproteins by phospholipid transfer protein J. Lipid Res., January 1, 2008; 49(1): 115 - 126. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. G. D. Silva, L. A. Schneeweis, S. C. Krishnan, X. Zhang, P. H. Axelsen, and W. S. Davidson The Structure of Apolipoprotein A-II in Discoidal High Density Lipoproteins J. Biol. Chem., March 30, 2007; 282(13): 9713 - 9721. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. K. Curtiss, D. T. Valenta, N. J. Hime, and K.-A. Rye What Is So Special About Apolipoprotein AI in Reverse Cholesterol Transport? Arterioscler. Thromb. Vasc. Biol., January 1, 2006; 26(1): 12 - 19. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |